Novo Nordisk Says CEO to Step Down Amid Stock Slump. The Shares Are Down 5%. -- Barrons.com

Dow Jones

16 May

By Elsa Ohlen

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of weight-loss drugs Ozempic and Wegovy after an eight-year tenure during which the it, for a period, became Europe's most valuable company.

It was a "mutual agreement," between Fruergaard Jørgensen and Novo Nordisk Board, the company said in a statement Friday.

"The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024," the company added.

Novo Nordisk stock fell 4.3% in midday trading in Denmark after having traded higher earlier in the day. Its American depositary receipts were down 5.7% to $62.39 in premarket trading.

The search for Fruergaard Jørgensen's successor is ongoing, and he will continue as CEO for a period to support a the transition, the company added.

The leadership change comes after a sustained period of decline for the stock. Shares are down about 50% over the past 12 months amid increased competition from U.S. rival Eli Lilly and disappointing data for its next-generation weight-loss drug CagriSema.

This is breaking news. Check back for more analysis soon.

Write to Elsa Ohlen at elsa.ohlen@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

May 16, 2025 07:45 ET (11:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535498399"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535498399\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535498399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535498399","market":"hk","top_or_hot":-1,"title":"Novo Nordisk Says CEO to Step Down Amid Stock Slump. The Shares Are Down 5%. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elsa Ohlen \n</p>\n<p>\n  Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of weight-loss drugs Ozempic and Wegovy after an eight-year tenure during which the it, for a period, became Europe's most valuable company. \n</p>\n<p>\n     It was a \"mutual agreement,\" between Fruergaard Jørgensen and Novo Nordisk Board, the company said in a statement Friday. \n</p>\n<p>\n     \"The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024,\" the company added. \n</p>\n<p>\n     Novo Nordisk stock fell 4.3% in midday trading in Denmark after having traded higher earlier in the day. Its American depositary receipts were down 5.7% to $62.39 in premarket trading. \n</p>\n<p>\n     The search for Fruergaard Jørgensen's successor is ongoing, and he will continue as CEO for a period to support a the transition, the company added. \n</p>\n<p>\n     The leadership change comes after a sustained period of decline for the stock. Shares are down about 50% over the past 12 months amid increased competition from U.S. rival Eli Lilly and disappointing data for its next-generation weight-loss drug CagriSema. \n</p>\n<p>\n     This is breaking news. Check back for more analysis soon. \n</p>\n<p>\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 16, 2025 07:45 ET (11:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Says CEO to Step Down Amid Stock Slump. The Shares Are Down 5%. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Says CEO to Step Down Amid Stock Slump. The Shares Are Down 5%. -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-16 19:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elsa Ohlen \n</p>\n<p>\n  Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of weight-loss drugs Ozempic and Wegovy after an eight-year tenure during which the it, for a period, became Europe's most valuable company. \n</p>\n<p>\n     It was a \"mutual agreement,\" between Fruergaard Jørgensen and Novo Nordisk Board, the company said in a statement Friday. \n</p>\n<p>\n     \"The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024,\" the company added. \n</p>\n<p>\n     Novo Nordisk stock fell 4.3% in midday trading in Denmark after having traded higher earlier in the day. Its American depositary receipts were down 5.7% to $62.39 in premarket trading. \n</p>\n<p>\n     The search for Fruergaard Jørgensen's successor is ongoing, and he will continue as CEO for a period to support a the transition, the company added. \n</p>\n<p>\n     The leadership change comes after a sustained period of decline for the stock. Shares are down about 50% over the past 12 months amid increased competition from U.S. rival Eli Lilly and disappointing data for its next-generation weight-loss drug CagriSema. \n</p>\n<p>\n     This is breaking news. Check back for more analysis soon. \n</p>\n<p>\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n</p>\n<p>\n     This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 16, 2025 07:45 ET (11:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535498399","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535498399","pubTimestamp":1747395900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Novo Nordisk CEO Lars Fruergaard Jrgensen will step down as CEO of the Danish maker of weight-loss drugs Ozempic and Wegovy after an eight-year tenure during which the it, for a period, became Europe's most valuable company.It was a \"mutual agreement,\" between Fruergaard Jrgensen and Novo Nordisk Board, the company said in a statement Friday.\"The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024,\" the company added.Novo Nordisk stock fell 4.3% in midday trading in Denmark after having traded higher earlier in the day. Its American depositary receipts were down 5.7% to $62.39 in premarket trading.The search for Fruergaard Jrgensen's successor is ongoing, and he will continue as CEO for a period to support a the transition, the company added.The leadership change comes after a sustained period of decline for the stock. Shares are down about 50% over the past 12 months amid incr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"诺和诺德表示首席执行官将因股价暴跌而辞职。股价下跌5%。——Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"By Elsa Ohlen \n\n\n  Novo Nordisk CEO Lars Fruergaard Jørgensen will step down as CEO of the Danish maker of weight-loss drugs Ozempic and Wegovy after an eight-year tenure during which the it, for a period, became Europe's most valuable company. \n\n\n     It was a \"mutual agreement,\" between Fruergaard Jørgensen and Novo Nordisk Board, the company said in a statement Friday. \n\n\n     \"The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024,\" the company added. \n\n\n     Novo Nordisk stock fell 4.3% in midday trading in Denmark after having traded higher earlier in the day. Its American depositary receipts were down 5.7% to $62.39 in premarket trading. \n\n\n     The search for Fruergaard Jørgensen's successor is ongoing, and he will continue as CEO for a period to support a the transition, the company added. \n\n\n     The leadership change comes after a sustained period of decline for the stock. Shares are down about 50% over the past 12 months amid increased competition from U.S. rival Eli Lilly and disappointing data for its next-generation weight-loss drug CagriSema. \n\n\n     This is breaking news. Check back for more analysis soon. \n\n\n     Write to Elsa Ohlen at elsa.ohlen@barrons.com \n\n\n     This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 07:45 ET (11:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}